{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T09:17:34Z","timestamp":1720689454928},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.3816\/clm.2008.s.008","type":"journal-article","created":{"date-parts":[[2008,10,25]],"date-time":"2008-10-25T01:14:38Z","timestamp":1224897278000},"page":"S128-S136","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S4","title":["Considerations with Newer Regimens for Indolent Non\u2013Hodgkin Lymphoma"],"prefix":"10.3816","volume":"8","author":[{"given":"Mathias","family":"Rummel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2008.s.008_bib1","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lym-phoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib2","doi-asserted-by":"crossref","first-page":"147a","DOI":"10.1182\/blood.V108.11.486.486","article-title":"Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up (F\/Up) of 7 years","volume":"108","author":"Colombat","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.008_bib3","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.008_bib4","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2013a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib5","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.008_bib6","doi-asserted-by":"crossref","first-page":"146a","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.008_bib7","doi-asserted-by":"crossref","first-page":"156a","DOI":"10.1182\/blood.V108.11.481.481","article-title":"MabThera (rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkins lymphoma (NHL)","volume":"108","author":"Marcus","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.008_bib8","first-page":"781a","article-title":"Results of a phase I\/II trial of pixantrone in combination with fludarabine, dexamethasone, and rituximabin the treatment of patients with relapsed\/refractory indolent non-Hodgkins lymphoma (NHL)","volume":"110","author":"Fayad","year":"2006","journal-title":"Blood"},{"issue":"18 suppl","key":"10.3816\/CLM.2008.s.008_bib9","first-page":"441s","article-title":"Comparative trial of BBR 2778 (pixantrone) + rituximab vs single agent rituximab in the treatment of relapsed\/refractory indolent non-Hodgkin's lymphoma (NHL)","volume":"24","author":"Santoro","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib10","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1046\/j.1365-2567.1998.00550.x","article-title":"Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma","volume":"94","author":"Vyth-Dreese","year":"1998","journal-title":"Immunology"},{"key":"10.3816\/CLM.2008.s.008_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/85251","article-title":"The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function","volume":"2","author":"Coyle","year":"2001","journal-title":"Nat Immunol"},{"key":"10.3816\/CLM.2008.s.008_bib12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0955-0674(99)80027-1","article-title":"Costimulatory regulation of T cell function","volume":"11","author":"Chambers","year":"1999","journal-title":"Curr Opin Cell Biol"},{"key":"10.3816\/CLM.2008.s.008_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3816\/CLM.2003.n.008","article-title":"Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma","volume":"3","author":"Younes","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.3816\/CLM.2008.s.008_bib14","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1200\/JCO.2005.09.018","article-title":"Phase I\/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma","volume":"23","author":"Czuczman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib15","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/annonc\/mdm114","article-title":"A phase I\/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma","volume":"18","author":"Leonard","year":"2007","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib16","unstructured":"Clinicaltrials.gov [Web site]. Gal\/Rit_FL. A phase III, randomized, double-blind study of galiximab in combination with rituximab compared with rituximab in combination with placebo for the treatment of subjects with relapsed or refractory, follicular non-Hodgkin's lymphoma. Available at: http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00363636?order=1"},{"key":"10.3816\/CLM.2008.s.008_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0960-9822(06)00057-1","article-title":"CD22 is a negative regulator of B-cell receptor signalling","volume":"7","author":"Nitschke","year":"1997","journal-title":"Curr Biol"},{"issue":"10 Pt 2","key":"10.3816\/CLM.2008.s.008_bib18","first-page":"3991S","article-title":"Epratuzumab: targeting B-cell malignancies through CD22","volume":"9","author":"Coleman","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"10 Pt 2","key":"10.3816\/CLM.2008.s.008_bib19","first-page":"3982S","article-title":"Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties","volume":"9","author":"Carnahan","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2008.s.008_bib20","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","article-title":"Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma","volume":"21","author":"Leonard","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib21","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1200\/JCO.2005.13.821","article-title":"Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma","volume":"23","author":"Leonard","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib22","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","article-title":"Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib23","unstructured":"Clinicaltrials.gov [Web site]. A phase III clinical trial of immunotherapy with humanized LL2 IgG (epratuzumab) in patients with low-grade follicular, B-cell non-Hodgkin's lymphoma refractory to Rituxan (rituximab). Available at: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00022685?term=epratuzumab&rank=5"},{"key":"10.3816\/CLM.2008.s.008_bib24","unstructured":"Clinicaltrials.gov [Web site]. A phase II trial of extended induction epratuzumab (Anti-CD22 monoclonal antibody) (CALGB IND #XXXXX) plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL). Available at: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00553501?term=epratuzumab&rank=11"},{"issue":"3 suppl 9","key":"10.3816\/CLM.2008.s.008_bib25","first-page":"S9-78","article-title":"Effect of alpha-interferons on immune function","volume":"24","author":"Herberman","year":"1997","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/10428190701704647","article-title":"Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group","volume":"49","author":"Kimby","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2008.s.008_bib27","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"104","author":"Cartron","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.008_bib28","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"issue":"suppl 2","key":"10.3816\/CLM.2008.s.008_bib29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1634\/theoncologist.12-S2-22","article-title":"The role of sargramostim (rhGM-CSF) as immunotherapy","volume":"12","author":"Waller","year":"2007","journal-title":"Oncologist"},{"key":"10.3816\/CLM.2008.s.008_bib30","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1056\/NEJM199312093292419","article-title":"Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: five-year follow-up","volume":"329","author":"Andersen","year":"1993","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.008_bib31","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","article-title":"Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial","volume":"16","author":"Solal-Celigny","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib32","first-page":"2644","article-title":"Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a","volume":"6","author":"Davis","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2008.s.008_bib33","first-page":"951","article-title":"Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma","volume":"86","author":"Sacchi","year":"2001","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2008.s.008_bib34","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1200\/JCO.2007.13.7729","article-title":"Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study","volume":"26","author":"Cartron","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12 Pt 1","key":"10.3816\/CLM.2008.s.008_bib35","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1158\/1078-0432.CCR-03-0658","article-title":"Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma","volume":"10","author":"Niitsu","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2008.s.008_bib36","unstructured":"Clinicaltrials.gov [Web site]. A phase II study of GM-CSF (sargramostim) and rituximab following autologous transplantation for relapsed follicular lymphoma. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00521014?term=GM-CSF+rituximab&cond=%22Lymphoma%2C+Follicular%22&rank=1"},{"key":"10.3816\/CLM.2008.s.008_bib37","unstructured":"Clinicaltrials.gov [Web site]. Randomized, open label, phase II trial comparing rituximab plus sargramostim to rituximab monotherapy for the treatment of relapsed follicular B-cell lymphoma. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00308087?term=GM-CSF+rituximab&cond=%22Lymphoma%2C+Follicular%22&rank=2"},{"key":"10.3816\/CLM.2008.s.008_bib38","unstructured":"Clinicaltrials.gov [Web site]. Single-arm, open-label, phase II trial of rituximab plus sargramostim for the treatment of newly diagnosed follicular B-cell lymphoma in adults. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00411086?term=GM-CSF+rituximab&cond=%22Lymphoma%2C+Follicular%22&rank=7"},{"key":"10.3816\/CLM.2008.s.008_bib39","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib40","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.008_bib41","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/annonc\/mdl393","article-title":"A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study","volume":"18","author":"Nitta","year":"2007","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/cbr.1997.12.177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs","volume":"12","author":"Demidem","year":"1997","journal-title":"Cancer Biother Radiopharm"},{"key":"10.3816\/CLM.2008.s.008_bib43","doi-asserted-by":"crossref","first-page":"243a","DOI":"10.1182\/blood.V110.11.792.792","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: final analysis of the GELA-GOELAMS FL2000 study with a 5-year followup","volume":"110","author":"Salles","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.008_bib44","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2003.07.113","article-title":"Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients","volume":"21","author":"Armitage","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib45","first-page":"99","article-title":"Acute myeloid leukemia and other myelopathic disorders following treatment with alkylating agents","volume":"1","author":"Bennett","year":"1987","journal-title":"Hematol Pathol"},{"key":"10.3816\/CLM.2008.s.008_bib46","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1182\/blood-2004-08-3035","article-title":"Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha","volume":"105","author":"McLaughlin","year":"2005","journal-title":"Blood"},{"issue":"4 suppl 13","key":"10.3816\/CLM.2008.s.008_bib47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/sonc.2002.34877","article-title":"Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives","volume":"29","author":"Rummel","year":"2002","journal-title":"Semin Oncol"},{"issue":"4 suppl 13","key":"10.3816\/CLM.2008.s.008_bib48","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/sonc.2002.34872","article-title":"Metabolism and mechanisms of action of bendamustine: rationales for combination therapies","volume":"29","author":"Gandhi","year":"2002","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib49","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents","volume":"14","author":"Leoni","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2008.s.008_bib50","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib51","doi-asserted-by":"crossref","first-page":"406a","DOI":"10.1182\/blood.V110.11.1351.1351","article-title":"Bendamustine is safe and effective in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma","volume":"110","author":"Kahl","year":"2007","journal-title":"Blood"},{"issue":"suppl 2","key":"10.3816\/CLM.2008.s.008_bib52","first-page":"149","article-title":"Bendamustine(B), vincristine(O), prednisolone(P) in relapsed and refractory low-grade non-Hodgkin's lymphomas (NHL)","volume":"77","author":"Blumenstengel","year":"1999","journal-title":"Ann Hematol"},{"issue":"suppl 3","key":"10.3816\/CLM.2008.s.008_bib53","first-page":"125","article-title":"Therapy of low grade non-Hodgkin's-lymphoma (NHL) with bendamustine and oral etoposide","volume":"10","author":"Ruffert","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00432-005-0023-2","article-title":"Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)","volume":"132","author":"Herold","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib55","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1080\/1042819042000223822","article-title":"Fludarabine and bendamustine in refractory and relapsed indolent lymphoma -a multicenter phase I\/II trial of the East German Society of Hematology and Oncology (OSHO)","volume":"45","author":"Koenigsmann","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2008.s.008_bib56","doi-asserted-by":"crossref","first-page":"120a","DOI":"10.1182\/blood.V110.11.385.385","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)","volume":"110","author":"Rummel","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.008_bib57","doi-asserted-by":"crossref","first-page":"766a","DOI":"10.1182\/blood.V108.11.2710.2710","article-title":"Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-Hodgkins lymphoma","volume":"108","author":"Van der Jagt","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.008_bib58","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/10428190701361828","article-title":"High anti-lymphoma activity of bendamustine\/mitoxantrone\/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)","volume":"48","author":"Weide","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"18 suppl","key":"10.3816\/CLM.2008.s.008_bib59","first-page":"449s","article-title":"Bendamustine and rituximab (BR) are effective in the treatment of relapsed or refractory indolent and mantlecell lymphomas: long-term follow-up of a phase II study","volume":"25","author":"Rummel","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib60","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00001813-200110000-00003","article-title":"Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas","volume":"12","author":"Heider","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.3816\/CLM.2008.s.008_bib61","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00432-002-0378-6","article-title":"High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's lymphomas","volume":"128","author":"Bremer","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.3816\/CLM.2008.s.008_bib62","first-page":"1057","article-title":"SDX-105 (bendamustine) inhibits growth of SU-DHL-1 and Daudi lymphoma xenografts in SCID mice","volume":"45","author":"Kanekal","year":"2004","journal-title":"Am Assoc Cancer Res"},{"key":"10.3816\/CLM.2008.s.008_bib63","first-page":"33","article-title":"Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases","volume":"87","author":"Chow","year":"2002","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2008.s.008_bib64","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1080\/10428190400004521","article-title":"Bendamustine\/mitoxantrone\/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study","volume":"45","author":"Weide","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2008.s.008_bib65","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/030089160108700611","article-title":"Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity","volume":"87","author":"Beggiolin","year":"2001","journal-title":"Tumori"},{"key":"10.3816\/CLM.2008.s.008_bib66","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1021\/jm00032a018","article-title":"6,9-Bis[(aminoalkyl)amin o]benzo[g]isoquinoline-5,10-diones. A novel class of chromophoremodified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations","volume":"37","author":"Krapcho","year":"1994","journal-title":"J Med Chem"},{"key":"10.3816\/CLM.2008.s.008_bib67","first-page":"43","article-title":"A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies","volume":"7","author":"Faivre","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2008.s.008_bib68","first-page":"888","article-title":"Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas","volume":"88","author":"Borchmann","year":"2003","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2008.s.008_bib69","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1023\/A:1011139016294","article-title":"Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma","volume":"12","author":"Borchmann","year":"2001","journal-title":"Ann Oncol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T15:04:17Z","timestamp":1589036657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011702748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":69,"alternative-id":["S1557919011702748"],"URL":"https:\/\/doi.org\/10.3816\/clm.2008.s.008","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}